Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit
暂无分享,去创建一个
Catrin Tudur Smith | Paula Williamson | Carrol Gamble | Alan Smyth | Ashley P Jones | C. Gamble | P. Williamson | C. Tudur Smith | A. Smyth | Ashley Jones | Simon Langton Hewer | S. L. Hewer
[1] Canary Wharf,et al. Reflection paper on risk based quality management in clinical trials , 2013 .
[2] S. Meredith,et al. MRC/DH/MHRA Joint Project Risk-adapted approaches to the management of clinical trials of investigational medicinal products , 2011 .
[3] P. Lachenbruch,et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, Statistics in medicine.
[4] C. Gamble,et al. The Role of Systematic Reviews in Pharmacovigilance Planning and Clinical Trials Authorisation Application: Example from the SLEEPS Trial , 2013, PloS one.
[5] Sheena McCormack,et al. The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial , 2012, Clinical trials.
[6] Taghrid Obied,et al. Oversight of clinical investigations- A risk based approach to monitoring , 2014 .
[7] Douglas G Altman,et al. Ensuring trial validity by data quality assurance and diversification of monitoring methods , 2008, Clinical trials.
[8] Sylvie Chevret,et al. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study. , 2011, Contemporary clinical trials.
[9] James D Neaton,et al. Monitoring the quality of conduct of clinical trials: a survey of current practices , 2011, Clinical trials.
[10] Catrin Tudur Smith,et al. The Value of Source Data Verification in a Cancer Clinical Trial , 2012, PloS one.
[11] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .